Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilastatin/imipenem/relebactam - Merck Sharp and Dohme

Next Previous
Drug Profile

Cilastatin/imipenem/relebactam - Merck Sharp and Dohme

Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; RECARBRIO; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatin

Latest Information Update: 12 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Anti-infectives; Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
  • Registered Bacteraemia; Bacterial infections
  • Phase II/III Gram-negative infections
  • No development reported Sepsis

Most Recent Events

  • 11 Dec 2025 Preregistration for Bacteraemia (In neonates, In infants, In children, In adolescents) in European Union (IV) prior to December 2025
  • 11 Dec 2025 Preregistration for Bacterial infections (In neonates, In infants, In children, In adolescents) in European Union (IV) prior to December 2025
  • 11 Dec 2025 Preregistration for Ventilator-associated-pneumonia (In neonates, In infants, In children, In adolescents) in European Union (IV) prior to December 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top